High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  He, Yi Feng ^a   Zhang, Mei Ying ^a   Wu, Xin ^b   Sun, Xiang Ju ^a   Xu, Ting ^b   He, Qi Zhi ^c   Di, Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MUCIN 2; PROSTAGLANDIN E2;

ADULT; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CELL DENSITY; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME INDUCTION; FEMALE; FLUORESCENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; POLARIZATION; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA, MUCINOUS; AGED; CYCLOOXYGENASE 2; CYSTADENOCARCINOMA, SEROUS; DINOPROSTONE; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MIDDLE AGED; MUCIN-2; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84891946295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079769     Document Type: Article

References (51)

1. Permuth-Wey J, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol Biol 472: 413-437. doi:10.1007/978-1-60327-492-0-20. PubMed: 19107446.
2. Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H et al. (2012) Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother 61: 1885-1903. doi:10.1007/s00262-012-1354-x. PubMed: 22986455.
3. Di Virgilio F (2012) Purines, purinergic receptors, and cancer. Cancer Res 72: 5441-5447. doi:10.1158/0008-5472.CAN-12-1600. PubMed: 23090120.
4. Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM et al. (2008) Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 9: 1076-1085. doi:10.1016/S1470-2045(08)70277-8. PubMed: 19012856.
5. Johansson ME, Ambort D, Pelaseyed T, Schütte A, Gustafsson JK et al. (2011) Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci 68: 3635-3641. doi:10.1007/s00018-011-0822-3. PubMed: 21947475.
6. Bafna S, Kaur S, Batra SK (2010) Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 29: 2893-2904. doi:10.1038/onc.2010.87. PubMed: 20348949.
7. Maher DM, Gupta BK, Nagata S, Jaggi M, Chauhan SC (2011) Mucin 13: structure, function, and potential roles in cancer pathogenesis. Mol Cancer Res 9: 531-537. doi:10.1158/1541-7786.MCR-10-0443. PubMed: 21450906.
8. Chen K, Gentry-Maharaj A, Burnell M, Steentoft C, Marcos-Silva L et al. (2013) Microarray glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J Proteome Res 12: 1408-1418. doi: 10.1021/pr3010474. PubMed: 23360124.
9. Comamala M, Pinard M, Thériault C, Matte I, Albert A et al. (2011) Downregulation of cell surface CA125/MUC16 induces epithelial-tomesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 104: 989-999. doi:10.1038/bjc. 2011.34. PubMed: 21326240.
10. Hu XF, Yang E, Li J, Xing PX (2006) MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther 6: 1261-1271. doi:10.1586/14737140.6.8.1261. PubMed: 16925492. (Pubitemid 44304694)
11. Tornos C, Soslow R, Chen S, Akram M, Hummer AJ et al. (2005) Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 29: 1482-1489. doi: 10.1097/01.pas.0000176429.88702.36. PubMed: 16224215. (Pubitemid 41513298)
12. Inaba T, Sano H, Kawahito Y, Hla T, Akita K et al. (2003) Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A 100: 2736-2741. doi: 10.1073/pnas.0435410100. PubMed: 12598658. (Pubitemid 36297568)
13. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612. doi: 10.1158/0008-5472.CAN-05- 4005. PubMed: 16423985. (Pubitemid 43165918)
14. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555. doi:10.1016/S1471-4906(02) 02302-5. PubMed: 12401408. (Pubitemid 35223554)
15. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33: 118-126. doi:10.1183/09031936.00065708. PubMed: 19118225.
16. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg A et al. (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLOS ONE 7: e47045. doi:10.1371/journal.pone.0047045. PubMed: 23077543.
17. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R et al. (2010) Tumor progression stage and anatomical site regulate tumorassociated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 176: 2972-2985. doi:10.2353/ajpath. 2010.090879. PubMed: 20431028.
18. Mantovani A, Porta C, Rubino L, Allavena P, Sica A (2006) Tumorassociated macrophages (TAMs) as new target in anticancer therapy. Drug Discov Today Ther Strateg 3: 361-366. doi:10.1016/j.ddstr. 2006.07.001. (Pubitemid 44774479)
19. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH et al. (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132-2141. doi:10.1172/JCI27648. PubMed: 16862213. (Pubitemid 44162322)
20. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE et al. (2010) IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24: 241-255. doi:10.1101/gad.1874010. PubMed: 20080943.
21. Shen Z, Seppänen H, Vainionpää S, Ye Y, Wang S et al. (2012) IL10, IL11, IL18 are differently expressed in CD14+ TAMs and play different role in regulating the invasion of gastric cancer cells under hypoxia. Cytokine 59: 352-357. doi:10.1016/j.cyto.2012.04.033. PubMed: 22595646.
22. Denny L, Hacker NF, Gori J (2006) Staging classifications and clinical practice guidelines for gynaecological cancers, 3rd ed. London: Elsevier.
23. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK et al. (1997) Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 183: 311-317. doi:10.1002/(SICI)1096-9896(199711)183:3. PubMed: 9422987. (Pubitemid 27505217)
24. Tashiro Y, Yonezawa S, Kim YS, Sato E (1994) Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol 25: 364-372. doi:10.1016/0046-8177(94)90144-9. PubMed: 8163269. (Pubitemid 24151121)
25. Boman F, Buisine MP, Wacrenier A, Querleu D, Aubert JP et al. (2001) Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study. J Pathol 193: 339-344. doi: 10.1002/1096- 9896(2000)9999:9999. PubMed: 11241413. (Pubitemid 32229865)
26. Ma J, Liu L, Che G, Yu N, Dai F et al. (2010) The M1 form of tumorassociated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10: 112. doi: 10.1186/1471-2407-10- 112. PubMed: 20338029.
27. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F et al. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7: 1048-1051. doi:10.1038/nm0901-1048. PubMed: 11533709. (Pubitemid 32937386)
28. Cardillo MR, Castagna G, Memeo L, De Bernardinis E, Di Silverio F (2000) Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res 19: 225-233. PubMed: 10965823. (Pubitemid 30490165)
29. Kasashima S, Kawashima A, Zen Y, Ozaki S, Kobayashi M et al. (2007) Expression of aberrant mucins in lobular carcinoma with histiocytoid feature of the breast. Virchows Arch 450: 397-403. doi: 10.1007/s00428-007-0381-z. PubMed: 17333267. (Pubitemid 46466394)
30. Shin JH, Bae JH, Lee A, Jung CK, Yim HW et al. (2010) CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol 40: 208-213. doi:10.1093/jjco/hyp150. PubMed: 19926591.
31. Espinosa I, Edris B, Lee CH, Cheng HW, Gilks CB et al. (2011) CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. Am J Pathol 179: 2100-2107. doi: 10.1016/j.ajpath.2011.06.021. PubMed: 21854753.
32. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K et al. (2010) Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101: 1913-1919. doi: 10.1111/j.1349-7006.2010.01614.x. PubMed: 20545696.
33. Takai H, Ashihara M, Ishiguro T, Terashima H, Watanabe T et al. (2009) Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Cancer Biol Ther 8: 2329-2338. doi:10.1158/1535-7163.MCT-09-0150. PubMed: 19838081.
34. Zhang J, Lu Y, Pienta KJ (2010) Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 102: 522-528. doi:10.1093/jnci/djq044. PubMed: 20233997.
35. Zhu XD, Zhuang Y, Ben JJ, Qian LL, Huang HP et al. (2011) Caveolaedependent endocytosis is required for class A macrophage scavenger receptor-mediated apoptosis in macrophages. J Biol Chem 286: 8231-8239. doi:10.1074/jbc.M110.145888. PubMed: 21205827.
36. Zhang B, Yao G, Zhang Y, Gao J, Yang B et al. (2011) M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 66: 1879-1886. doi:10.1590/S1807-59322011001100006. PubMed: 22086517.
37. Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundström J et al. (2012) Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 131: 864-873. doi:10.1002/ijc.26457. PubMed: 21952788.
38. Ghosh DK, Misukonis MA, Reich C, Pisetsky DS, Weinberg JB (2001) Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. Infect Immun 69: 7703-7710. doi:10.1128/IAI.69.12.7703-7710.2001. PubMed: 11705951. (Pubitemid 33086600)
39. Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K et al. (2012) Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLOS ONE 7: e46342. doi:10.1371/journal.pone.0046342. PubMed: 23029485.
40. Neeman E, Zmora O, Ben-Eliyahu S (2012) A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res 18: 4895-4902. doi:10.1158/1078-0432.CCR-12- 1087. PubMed: 22753587.
41. Hamberg M, Samuelsson B (1971) On the metabolism of prostaglandins E 1 and E 2 in man. J Biol Chem 246: 6713-6721. PubMed: 5126221.
42. Torroella-Kouri M, Silvera R, Rodriguez D, Caso R, Shatry A et al. (2009) Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res 69: 4800-4809. doi: 10.1158/0008-5472.CAN-08-3427. PubMed: 19458073.
43. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A et al. (2011) M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 187: 1157-1165. doi:10.4049/jimmunol.1100889. PubMed: 21709158.
44. Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R et al. (2011) COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 32: 1333-1339. doi:10.1093/carcin/bgr128. PubMed: 21730361.
45. Feng H, Ghazizadeh M, Konishi H, Araki T (2002) Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 32: 525-529. doi:10.1093/jjco/hyf111. PubMed: 12578901. (Pubitemid 43102758)
46. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK et al. (1997) Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 183: 311-317. doi:10.1002/(SICI)1096-9896(199711)183:3. PubMed: 9422987. (Pubitemid 27505217)
47. Harrison ML, Jameson C, Gore ME (2008) Mucinous ovarian cancer. Int J Gynecol Cancer 18: 209-214. doi:10.1111/j. 1525-1438.2007.01022.x. PubMed: 17624989. (Pubitemid 351365218)
48. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E et al. (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8): viii7-viii12. doi:10.1093/annonc/mdi825.PubMed: 16239238. (Pubitemid 41631227)
49. Emi M, Asaoka H, Matsumoto A, Itakura H, Kurihara Y et al. (1993) Structure, organization, and chromosomal mapping of the human macrophage scavenger receptor gene. J Biol Chem 268: 2120-2125. PubMed: 8093617. (Pubitemid 23033622)
50. Matsumoto A, Naito M, Itakura H, Ikemoto S, Asaoka H et al. (1990) Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions. Proc Natl Acad Sci U S A 87: 9133-9137. doi:10.1073/pnas.87.23.9133. PubMed: 2251254. (Pubitemid 120030579)
51. Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M et al. (2004) Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 306: 1558-1561. doi:10.1126/science.1101909. PubMed: 15567863. (Pubitemid 39564952)